NCT00491998View on ClinicalTrials.gov

PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Parkinson's Disease
Interventions
DRUG

V1512

6 doses of IMP at 2-hourly intervals

DRUG

V1512

3-hourly dosing

DRUG

V1512 and Entacapone

4 doses of IMP and Entacapone at 3-hourly intervals

Trial Locations (1)

00163

IRCCS San Raffaele Pisana, Roma

Sponsors
All Listed Sponsors
collaborator

Cita NeuroPharmaceuticals

INDUSTRY

collaborator

Syneos Health

OTHER

lead

Vernalis (R&D) Ltd

INDUSTRY